Back to top
more

Edwards Lifesciences (EW)

(Delayed Data from NYSE)

$77.93 USD

77.93
3,238,557

-0.68 (-0.87%)

Updated Aug 7, 2025 04:00 PM ET

After-Market: $77.93 0.00 (0.00%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value F Growth A Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 40% (147 out of 246)

Industry: Medical - Instruments

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Here's Why You Should Invest in Edwards Lifesciences (EW) Now

by Zacks Equity Research

Investors continue to be optimistic about Edwards Lifesciences' (EW) performance.

Zacks Equity Research

Edwards Lifesciences Sapien 3 System Recall Classified Class I

by Zacks Equity Research

Edwards Lifesciences (EW) initiated the Field Corrective Action after receiving reports of 17 injuries and a death from the use of the Sapien 3 Ultra delivery system.

Zacks Equity Research

Why Is Edwards Lifesciences (EW) Up 3.2% Since Last Earnings Report?

by Zacks Equity Research

Edwards Lifesciences (EW) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Zacks Equity Research

Edwards Lifesciences' (EW) SAPIEN 3 TAVR Receives FDA Nod

by Zacks Equity Research

Edwards Lifesciences (EW) plans a commercial introduction of SAPIEN 3 Ultra in Europe.

Zacks Equity Research

HMS Holdings (HMSY) Soars to 52-Week High, Time to Cash Out?

by Zacks Equity Research

HMS Holdings (HMSY) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

Zacks Equity Research

Here is Why Growth Investors Should Buy Edwards Lifesciences (EW) Now

by Zacks Equity Research

Edwards Lifesciences (EW) could produce exceptional returns because of its solid growth attributes.

Zacks Equity Research

Edwards Lifesciences Corporation (EW) Shares March Higher, Can It Continue?

by Zacks Equity Research

As of late, it has definitely been a great time to be an investor in Edwards Lifesciences Corporation (EW).

Zacks Equity Research

Edwards Lifesciences (EW) Beats on Q2 Earnings, Ups EPS View

by Zacks Equity Research

Edwards Lifesciences (EW) Q2 results benefit from higher revenues, strong segmental performance and gross margin expansion.

Zacks Equity Research

Edwards Lifesciences (EW) Q2 Earnings and Revenues Top Estimates

by Zacks Equity Research

Edwards Lifesciences (EW) delivered earnings and revenue surprises of 3.76% and 4.00%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

What's in Store for Edwards Lifesciences' (EW) Q2 Earnings?

by Zacks Equity Research

Edwards Lifesciences (EW) is likely to deliver a solid second quarter on robust segmental performance.

Zacks Equity Research

Edwards Lifesciences (EW) Reports Next Week: Wall Street Expects Earnings Growth

by Zacks Equity Research

Edwards Lifesciences (EW) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Kevin Cook headshot

Bull of the Day: Penumbra (PEN)

by Kevin Cook

This $6 billion innovator removes blood clots and the deadly shadow of stroke with catheter-based aspiration technologies

Zacks Equity Research

Edwards Lifesciences Recalls Heart Device on Balloon Rupture

by Zacks Equity Research

Shares of Edwards Lifesciences (EW) decline post product recall news.

Urmimala Biswas headshot

CMS' Final Verdict on TAVR: A Boon or Bane for MedTech?

by Urmimala Biswas

While the industry bigwigs are keen to welcome the new CMS ruling, companies like Heart Valve Voice US are not lagging to pen their resistance against a revised policy.

Zacks Equity Research

HOLX or EW: Which Is the Better Value Stock Right Now?

by Zacks Equity Research

HOLX vs. EW: Which Stock Is the Better Value Option?

Zacks Equity Research

DexCom and Companion Medical Collaboration to Support CGM

by Zacks Equity Research

The collaboration enables InPen users to display real-time insulin data in Dexcom's (DXCM) CLARITY Diabetes Management Software.

Zacks Equity Research

Why Is Edwards Lifesciences (EW) Down 2.9% Since Last Earnings Report?

by Zacks Equity Research

Edwards Lifesciences (EW) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Zacks Equity Research

HOLX vs. EW: Which Stock Is the Better Value Option?

by Zacks Equity Research

HOLX vs. EW: Which Stock Is the Better Value Option?

Kevin Cook headshot

Bull of the Day: Penumbra (PEN)

by Kevin Cook

This $4 billion innovator removes blood clots and the deadly shadow of stroke with catheter-based aspiration technologies

Zacks Equity Research

Masimo Gets CE Mark for ANI Module, Enhances Root Platform

by Zacks Equity Research

Masimo (MASI) obtains CE mark of the ANI module for the Masimo Root Patient Monitoring and Connectivity Hub, which is likely to strengthen its expanding Root platform.

Zacks Equity Research

Edwards Lifesciences (EW) Q1 Earnings Beat, EPS View Raised

by Zacks Equity Research

Edwards Lifesciences (EW) gains on strong segmental contributions in Q1.

Zacks Equity Research

Edwards Lifesciences Takes Over CAS Medical Systems for $100M

by Zacks Equity Research

This CASMED acquisition is expected to strengthen Edwards Lifesciences' (EW) critical care portfolio and expand its footprint in the smart monitoring technology market.

Zacks Equity Research

What's in Store for Edwards Lifesciences' (EW) Q1 Earnings?

by Zacks Equity Research

Edwards Lifesciences (EW) expects to gain from core Critical Care product group in Q1.

Zacks Equity Research

Edwards Lifesciences (EW) Earnings Expected to Grow: Should You Buy?

by Zacks Equity Research

Edwards Lifesciences (EW) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

Can Retail Pharmacy USA Lift Walgreens' (WBA) Q2 Earnings?

by Zacks Equity Research

Widening pharmacy network, healthy prescription volumes along with contributions from Rite Aid are expected to contribute to Walgreens Boots' (WBA) top line in the fiscal second quarter.